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Introduction
Colorectal cancer (CRC) is the third most common 
cancer after lung and breast cancer and the fourth leading 
cause of oncological death in the world, with an estimated 
1.4 million cases and 700,000 deaths occurring in 2012 
(Torre et al., 2015; Zare-Bandamiri et al., 2017). The 
incidence of this cancer varies in the world. Nearly, 55% 
of these cases have occurred in highly developed countries, 
with the highest rates in Australia and New Zealand, and 
the lowest in the countries of West Africa (Ferlay et al., 
2015). 
CRC is one of the most common cancers in Iran, which 
has increased in recent years. The incidence of this cancer 
in Iran is lower than other developed countries; however, 
in - recent decades, this rate has increased significantly. 
According to national reports of Iran cancer registration in 
2009, colorectal cancer is the third most common cancer 
in women and the fourth most common cancer in men 
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(Kumar et al., 2010). 
The survival rate is one of the main indicators for 
evaluating the effect of healthcare, disease control, and 
measuring the effect of treatment. Survival rates are 
defined as the proportion of people with the same type 
and stage of cancer that is living in a specific period of 
time after the diagnosis(team, 2017).
There is a wide geographical distribution in the survival 
rates of patients with colorectal cancer. The 5-year survival 
rate varies from 65% in the USA (team, 2017) to 64% in 
Korea and less than 8% in the countries of sub-Saharan 
Africa like Gambia and Uganda (Sankaranarayanan et al., 
2011). Also, the 5-year survival rate of colorectal cancer 
in Iran varies from 27% to 85% (Mehrabani et al., 2012; 
Payandeh et al., 2016b).
 Different prognostic factors can influence the 
survival rates of CRC like age, gender, race, histology 
type, tumor grade, tumor size, tumor stage, regional 
lymph nodes metastasis, pathologic stage, and location of 
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tumor (Park et al., 1999; Moghimi-Dehkordi et al., 2008; 
Moghimi-Dehkordi et al., 2009; Ghazali et al., 2010). One 
of the most important factors that affect the survival rate 
in a patient with colorectal cancer is gender. The result 
of different studies indicated that the 5-year survival rate 
in women was significantly better than men (Wichmann 
et al., 2001; Koo and Leong, 2010; Majek et al., 2013). 
Another important prognostic factor is the location of the 
tumor. A different study indicated that the survival rate 
in rectum cancer was better than the colon ones and it is 
also depending on the stage of diagnosis (Meguid et al., 
2008; Hemminki et al., 2010; Lee et al., 2013; Phipps et 
al., 2013). 
Several studies had conducted to estimate the survival 
rate of colorectal cancer in Iran. But due to the differences 
between the results of previous studies, there is no 
consensus on the survival of colorectal cancer in Iran. 
Therefore, the aim of this study was to summarize the 
pooled survival rate of colorectal cancer in Iran. 
Materials and Methods
We followed the preferred reporting items for 
systematic reviews and meta-analyses (PRISMA) to 
perform and report this study (Moher et al., 2009).
Data source and search strategy
In this systematic review and meta-analysis, two 
reviewers independently searched an international 
database such as PubMed/Medline, Web of Science 
(ISI), Scopus, ProQuest, Science Direct, Embase and 
Google Scholar, and Iranian databases such as MagIran, 
IranMedex, and Scientific Information Databank (SID) 
up to December 1st 2017. We conducted initial search 
strategy using MeSH terms like “Colorectal Neoplasms” 
AND “Survival Rate”,set of proper keywords, including 
“Survival” OR “survive” OR “Prognosis”, “Colorectal 
cancer” OR “Colon cancer” OR “Rectum cancer”, 
and “Iran”. Finally, we checked the reference list of 
all included studies, to avoid missing any relevant 
articles. No limitations in terms of language and date of 
publications were considered in this study. The EndNote 
software (version X7, for Windows, Thomson Reuters, 
Philadelphia, PA, USA) was used to facilitate screening 
the result of the systematic search.
Study selection
All cohort studies that reported the survival rate or 
survival time and longevity of patient diagnosed with 
colorectal cancer among an Iranian population, without 
any limitation up to December 1st, 2017 were included 
in this study. Studies that discussed colorectal cancer 
but they did not report the survival rate or they had 
insufficient information were excluded from the study. The 
conference proceedings, letters, review and meta-analysis, 
cross-sectional, case report, and case series studies were 
also excluded. The two authors (KH, M, and E, SH) 
independently reviewed the search result by title, abstract 
and full text and disagreement between two authors were 
resolved by discussion or with a third author (M, KH). The 
details of the screening process and the study inclusion 
are shown in Figure 1.
Quality assessment and data extraction
In order to assess the risk of bias in all full-text 
articles included in this study, we used the recommended 
STROBE checklist (Von Elm et al., 2014) as follows: (a) 
clearly defined the source of participant selection, (b) 
clearly defined the eligibility criteria, (c) explain how to 
measure the exposure, (d) explain how to measure the 
outcome, (e) give the follow up information, (d) explain 
about sample size and power of the study. The quality of 
the included studies was assessed independently by two 
authors (KH, M, and E, SH). The studies were classified 
in three categories by using this checklist, which includes: 
low quality if each study obtained 30-59% of the total 
score, intermediate quality if each study retrieved 60-79% 
of the total score, and more than 70% considered as high 
quality. The value of weighted kappa statistic between 
author agreements was 86%. After confirming the quality 
of each study, two authors (KH, M, and E, SH) were 
independently extracted the data to the pre-specified data 
extraction sheet in Microsoft Excel. Variables extracted 
from each eligible study included: first author name, year 
of publication, period of study, location of study, study 
design, median follow up time, source of data, type of 
statistical analysis, sample size, mean age, the survival 
rate of one, three and five years with standard error or 
95% confidence interval(CI).
Statistical analysis
We generated 1, 3 and 5 year pooled survival rate by 
using Der-Simonies and Laird’s random-effect models. 
To calculate the standard error of survival rate and its 
variance, the 1 to 5-year survival rate in each study was 
considered as a binomial distribution. To graphically 
display the combined estimate of one, three and five-year 
survival rate, we used the metaprop command in Stata11. 
The metaprop command was specific to binomial data 
and for proportions near boundaries (i.e., in this instance 
100% at 1-year survival or zero at stage IV) which allows 
computation of exact binomial and score test-based 
confidence intervals by allowing Freeman-Tukey double 
arcsine transformation to stabilize the variances. We used a 
Chi-squared test at the 5 % significance level (p <0.05) and 
I2  index to determine the statistical heterogeneity between 
studies. To find the potential source of heterogeneity we 
used meta-regression model with a suspected variable such 
as; sample size, publication year and location of study. 
Furthermore, we used subgroup analysis by gender, tumor 
site, and location of a study to determine the source of 
heterogeneity. Sensitivity analysis was done to investigate 
the effect of each study on the pooled 1, 3 and 5-year 
survival rate. In this study, the publication bias was not 
assessed because the probability of survival is always a 
positive number between zero and one and therefore, if we 
saw asymmetry in funnel plots it is due to the distribution 
of all studies on the right side of the vertical line that which 
is not related to publication bias.  
We used Microsoft Excel 2010 to preparing data 
extraction sheet. Also, we used Stata11 (StataCorp, 
College Station, TX, USA) to conducted meta-analysis. 
Asian Pacific Journal of Cancer Prevention, Vol 20 15
DOI:10.31557/APJCP.2019.20.1.13
Survival Rate of Colorectal Cancer in Iran: A Systematic Review and Meta-Analysis 
were calculated 0.84 (95% CI: 0.81-0.87), 0.64 (95%CI: 
0.59-0.70), and 0.54 (95%CI:0.49-0.58), respectively. The 
heterogeneity index (I2 ) for 1, 3 and 5 year survival rate 
was 95.05%, 96.6% and 96.6%, respectively, that revealed 
the high heterogeneity between studies. To reduce the high 
heterogeneity between studies we performed subgroup 
analysis. According to the subgroup analysis, the pooled 
1, 3 and 5 year survival rate in male subgroup, were 0.83 
(95%CI: 0.79-0.88), 0.55 (95%CI: 0.53-0.57) and 0.44 
(95%CI: 0.40-0.48), respectively. In female subgroup, the 
pooled 1, 3 and 5 year survival rate were 0.84 (95%CI: 
0.80-0.88), 0.57 (95%CI: 0.52-0.63) and 0.50 (95%CI: 
0.44-0.56), respectively. Furthermore, the result of 
subgroup analysis based on the tumor site revealed that, 
the pooled 1, 3 and 5 year survival rate in colon cancer 
subgroup were 0.90 (95%CI:0.87-0.93), 0.69 (95%CI: 
0.63-0.75) and 0.60 (95%CI: 0.49-0.70) , respectively. 
In rectum cancer subgroup the pooled 1, 3 and 5 year 
survival rate were 0.88 (95%CI: 0.81-0.95), 0.73 (95%CI: 
0.62-0.83) and 0.54 (95%CI: 0.36-0.69), respectively. 
Results
Description of study
After initial search and screening by title, abstract 
and full text, 38 studies were enrolled according to the 
eligibility criteria which contain 19,160 patients, of the 
61% were male (Figure1, Table 1, 2, 3). From the total 
sample size of included studies, 10309 (53.8%) patient 
were from Tehran, 1,527 (7.96%) patient were from the 
south, 1,291 (6.73%) subjects from the west, 859 (4.48%) 
patients from center and 413 (2.15%) and 227 (1.18%) 
patients were from the east and the north, respectively. We 
have two national studies that comprised 4,534 (23.66%) 
subjects from the whole country. The mean age of the 
patients with colorectal cancer included in this study 
was 53.1 years. 
Survival rate
Using the random effect model, the pooled 1, 3 and 
5 year survival rate of patient with colorectal cancer 





















1 Abbasi Asl M et al (2015) 2015 2007-2009 Tehran 88 56±13.91 79.2 63.7 52.5 46.2 39.6 _
2 Abdolalian Z et al (2016) 2016 1987-2012 Tehran 232 18-82 _ _ 90 _ 72 64
3 Allahyari A et al (2016) 2016 2009-2015 Mashhad 96 57.8 _ _ _ 76 _ _
4 Ansari R et al (2007) 2007 1995-2003 Tehran 237 58.1±14.8 80 _ _ _ 49 _
5 Dianatinasab M (2016) 2016 2009-2014 Shiraz 220 _ 95 _ 87 _ 51 _
6 Esna-Ashari F et al (2008) 2009 2000-2004 Iran 2342 58.1±14.7 79.2 65 57.3 51.7 47.3 _
7 Faghihzade S et al (1998) 1998 1986-1990 Tehran 216 _ 86 64 51.6 48.9 40.6 _
8 Fatemi R et al (2015) 2015 2004-2013 Tehran 107 53.5±12.6 _ _ _ _ 73.8 _
9 Hashemian A.H et al (2017) 2017 2001-2007 Tehran 1127 _ 91.2 _ 73.2 _ 61 _
10 Madadizadeh F et al (2017) 2017 2005-2010 Fars 561 55.7±13.6 _ _ _ _ 59.6 _
11 Mehrabani D et al (2012) 2012 2003-2008 Shiraz 243 58.6±13.5 93.9 _ 50.3 _ 27.02 _
12 Mehrkhani F et al (2009) 2008 1999-2002 Tehran 1090 50.5±1.51 72 _ 54 _ 47 _
13 Moghimi-Dehkordi B et al 
(2008)
2008 2002-2007 Tehran 1127 53.5±14.3 91.1 _ 73.1 _ 61 47.9
14 Moradi A et al (2009) 2009 2000-2005 Iran 2192 57.8±14.9 84 68 54 43 41 _
15 Nasiri Sh et al (2010) 2010 1999-2002 Tehran 109 50.5±16.1 72 _ 54 _ 47 _
16 Omidvari sh et al (2013) 2013 2004-2010 Shiraz 153 57.15 _ _ _ _ 69.4 _
17 Parsaee R et al (2015) 2015 2006-2011 Mashhad 241 56.6 ± 0.9 81 66 53 44 _ _
18 Payandeh M et al (Payandeh 
et al., 2016a)
2016 2002-2014 Kermanshah 183 54.2±13.2 _ _ _ _ 84.6 _
19 RahimiPordanjani S 
(Chahmatki et al., 2016)
2016 2000-2010 Chaharmahal 
and Bakhtiari
452 59.1±19.9 85.7 _ _ _ 71.9 52.5
20 Rasouli M.A et al (2017) 2017 2009-2014 Kurdistan 335 60.5±1.12 87 69 57 42 33 _
21 Roshanaei G et al (2014) 2014 2005-2013 Hamadan 169 56.4±14.5 89 _ 54 _ 31 _
22 Saeedi Saedi H et al (2009) 2009 2001-2006 Mashhad 76 50 _ _ 68.2 _ _ _
23 Safaee A et al (2012) 2009 2002-2007 Tehran 1127 53 _ _ _ _ 61 _
24 Saki Malehi A et al (2012) 2012 2000-2007 Tehran 739 59.7±12.85 _ _ _ _ 63.3 _
25 Semnani S et al (2016) 2015 2006-2007 Golestan 227 54 71 _ 52 _ 44 _
26 Vakili M et al (2014) 2014 2001-2011 Yazd 604 58.9±19.9 72.2 _ _ _ 50.1 39.8
27 Zare-Bandamiri M et al 
(2016)
2016 2005-2010 Shiraz 570 55.8±23.6 _ _ _ _ 56.9 _
28 Zaargar A et al ( 2016) 2016 2007-2009 Qazvin 35 64.73±13.2 96 _ 86 _ 75 _
29 Safaee A (2010) 2010 2002-2005 Tehran 110 50.1 92.6 _ 80.1 _ 41.3 _
Table1. Characteristics of Included Studies in Meta-Analysis (Colorectal Cancer) 
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Meta-regression analysis
To identify the effect of the potential variable like 
the year of study, sample size and location of study 
as a source of heterogeneity, we used meta-regression 
analysis (Table 4). In the univariable model there was no 
significant association between included variables and 
pooled 1, 3 and 5-year survival rate (p-value>0.05). In 
multivariable meta-regression model, only there was a 
significant association between year of study and pooled 
5-year survival (β= 18.9, P=0.01). 
Sensitivity analysis
According to the result of sensitivity analysis that 
indicated in Table 5, after omitting each study there 
were no significant changes in the pooled 1, 3, and 5year 
survival rate of the patients with CRC.























1 Akhavan A et 
al (2014)
2014 2004-2012 Yazd Colon _ _ _ _ _ _ _
Rectum 119 97 _ 88 _ 55 _
2 Akhoond M et 
al (2010)
2010 2002-2007 Tehran 53.5±14.3 Colon 802 88.7 77.9 68.5 61.4 56.8 _
Rectum 392 89.1 74.2 60.7 47.1 41.9 _
3 Amirifard N et 
al (2016)
2016 2012-2015 Kermanshah 57.6±12.5 Colon 25 _ 71 _ _ _ _
Rectum 25 _ 76 _ _ _ _
4 Amirifard N et 
al (2016)
2016 2011-2016 Kermanshah 52.8±14.5 Colon _ _ _ _ _ _ _




2009 2002-2007 Tehran 55±37.6  Colon 802 91.7 83.7 75.9 69 63.3 _
Rectum 392 96 91.2 84 78.2 76 _
6 Fatemi R et al 
(2015)
2015 2004-2013 Tehran 53.5±12.6 Colon NR _ _ _ _ 75.9 _
Rectum NR _ _ _ _ 70 _
7 Gohari M et al 
(2011)
2011 2002-2007 Tehran 53.7±14.6 Colon 790 92 _ 71 _ 48 _
Rectum 291 86 _ 71 _ 42 _
8 Heidarnia M.A 
et al (2013)
2013 2005-2006 Tehran 63±11.8 Colon 580 _ _ _ _ 68.3 _
Rectum _ _ _ _ _ _ _
9 Sanei B et al 
(Sanei et al., 
2013)
2013 2003-2012 Isfahan 58.9±13.8 Colon _ _ _ _ _ _ _
Rectum 101 63.6 _ _ _ 40.7 _
Table 2. Characteristics of Included Studies in Meta-Analysis (Colon and Rectum Cancer) 
Figure 1. Flowchart of Search and Studies Selection
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Discussion
In this meta-analysis, we estimated the pooled 1, 3, 
and 5 year survival rates of patient with colorectal cancer 
in Iran. 
The pooled 1, and 3 year survival rates in our study 
were 0.84 (95% CI: 0.81-0.87) and 0.64 (95%CI: 
0.59-0.70), respectively. In a study conducted in India 
in 2001 the 1 and 3 year survival rates were reported 
63.4 and 42.2, respectively (Yeole et al., 2001), that 
was lower than the results of our study. Otherwise, in 
a study by Coleman in 2011 the 1-year survival rate in 
Australia, Canada, Denmark, Norway, Sweden, and the 
UK was reported by 84.9, 83.5, 77.7, 82.4, 83.8, and 74.7, 
respectively (Coleman et al., 2011). The result of this study 
is consistent with the finding of our study. In a study from 
China in 2013, the 3year survival rate was reported 0.74 
(Yuan et al., 2013). The 5-year survival rate in our study 








5 year survival 
95%CI
1 Tumor site Colorectal 19 0.84 (0.81-0.87) 18 0.64 (0.59-0.70) 26 0.54 (0.49-0.58)
Colon 4 0.90 (0.87-0.93) 4 0.69 (0.63-0.75) 5 0.60 (0.49-0.70)
Rectum 6 0.88 (0.81-0.95) 6 0.73 (0.62-0.83) 6 0.54 (0.36-0.69)
2 Gender Male 6 0.83 (0.79-0.88) 3 0.55 (0.53-0.57) 7 0.44 (0.40-0.48)
Female 6 0.84 (0.80-0.88) 3 0.57 (0.52-0.63) 7 0.50 (0.44-0.56)
Table 3. Result of Subgroup Analysis for Estimating the Pooled 1, 3, and 5 Year Survival Rate in Patient with Colorectal 
Cancer
Univariable Model Multivariable Model
Survival rate Variable β SE P-value β SE P-value
1 year survival rate Year of study -0.29 4.4 0.94 0.41 6.2 0.9
Sample size 1.5 4.07 0.7 0.93 5 0.8
Location -1.1 3.9 0.7 -0.95 5 0.8
3 year survival rate Year of study 3.6 6.9 0.6 7.3 7.6 0.3
Sample size 3.3 6.1 0.5 2.8 6.6 0.6
Location -9.5 5.5 0.1 -10.7 6 0.09
5 year survival rate Year of study 9.7 6 0.1 18.9 7.1 0.01
Sample size -0.88 7 0.9 7.4 7.05 0.3
Location -3 6 0.6 -11 6.2 0.09
Table 4. Meta-Regression Analysis for Assessing the Effect of Suspected Variables on the Pooled 1, 3, 5 and 10 Year's 
Survival
Figuer 2. Forest Plot of Pooled 1 Year Survival Rate in Patient with Colorectal Cancer
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was 0.54 (95%CI: 0.49-0.58). In studies that conducted in 
developing countries like India in 2001 (Yeole et al., 2001) 
and in Malaysia in 2010 (Ghazali et al., 2010), the 5-year 
survival rate was reported 33.6 and 34.3 respectively.  
In a study from Japan in 2005, the 5-year survival rate 
was reported 61.4 (Shiono et al., 2005). Also, studies that 
conducted in Germany in 2012, USA, England, France, 
and Italy were reported the 5-year survival rate 65, 65, 
52.7, 60.3 and 59.3 respectively (Brenner et al., 2012; 
Majek et al., 2012; team, 2017). And also in a study 
conducted in China, the 5-year survival rate was reported 
0.68 (Yuan et al., 2013). 
The 5 year survival rate of patients with colorectal 
cancer in our country is lower than the developed regions. 
Therefore, we conclude that the survival rate of patients 
with colorectal cancer in Iran is between developed and 
developing countries.
The survival rate of CRC patient in Iran like other 
Figuer 3. Forest Plot of Pooled 3 Year Survival Rate in Patient with Colorectal Cancer
Figuer 4. Forest Plot of Pooled 5 Year Survival Rate in Patient with Colorectal Cancer
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patients in the world depends on various factors such 
as demographic, pathologic and tumor characteristics, 
geographical distribution and gene mutation or having 
a family history (Dolatkhah et al., 2015; Rafiemanesh 
et al., 2016). But the most important factor for Iranian 
CRC patient is that they disease diagnosed in advanced 
stage (Aryaie et al., 2013; Dolatkhah et al., 2015). So this 
significant difference in 5-year survival rate may be due to, 
poorly established screening program like the fecal occult 
blood test, sigmoidoscopy and colonoscopy and limited 
accessibility in developing region (Sankaranarayanan et 
al., 2011). 
According to the high heterogeneity between the 
results of the included studies, we used subgroup analysis. 
The results of meta-analysis in subgroup based on the 
tumor site revealed that the pooled 1 and 5 year survival 
rate in colon cancer was better than the rectum cancer and 
only 3-year survival rate was better in rectum cancer than 
the colon cancer. 
In a study from Malaysia in 2010, the 5-year survival 
rate in colon cancer was reported 0.44 and 0.23 for rectum 
cancer (Ghazali et al., 2010). In China, in 1992-1995 
the 5-year survival rate in Colon and rectum cancer was 
reported at 0.43 and 0.41 respectively (Xiang et al., 2011). 
The result of these studies was similar to the results of 
our study.
The result of studies in USA (team, 2017) and England 
(Morris et al., 2011) revealed that the 5-year survival rate 
is slightly higher for rectal cancer than colon cancer.  
The result of some studies suggest that, the different 
site of tumors in colorectal cancer have been influenced 
by different risk factors and may have different biological 
and molecular profile, that they can results in differences 
in survival rate (Andrieu et al., 2004; Mahipal et al., 
2006; Kim et al., 2007; Yamauchi et al., 2012; Phipps et 
al., 2013). In one study the differences between survival 
rates by tumor site were dependent on stage at diagnosis, 
for example, there were no differences in survival of colon 
and rectum cancer in early stage, but in the advanced stage, 
patient with rectum cancer have better survival than colon 
cancer (Lee et al., 2013). Other studies claimed that colon 
cancer has a better response to antitumor drugs than the 
rectum cancer (Ueo et al., 1991; Lee et al., 2013) and 
patient with colon cancer has better prognosis than rectum 
cancer (Li et al., 2007; Lee et al., 2013).
The results of subgroup analysis based on gender 
indicate that, for all 1, 3, and 5 years, the survival rates 
for women were better than men. 
In a study in Germany in 2013 (Majek et al., 2013) and 
Cuba in 1994-1995 (Garrote et al., 2011) the age-specific 
5-year survival rate in women was better than men that 
were similar to the result of our study. 
The reason for better survival in women than men may 
be due to higher participation rate in women compared in 
men for screening programs like fecal occult blood test 
and colonoscopy (Stock et al., 2011; Pox et al., 2012; 
Majek et al., 2013). The most important factor for better 
survival in women is female gonadal hormones that have 
a protective effect and influence on the immune system. 
On the other hand, testosterone has a destructive effect on 
the immunological response (Parkin et al., 2005; Santarelli 
et al., 2008; Haggar and Boushey, 2009). 
Limitation
One of the most important factors that influence the 
survival of patients with colorectal cancer was the stage 
of diagnosis. The 5year survival rate was ranged from 
90% in localized stage, 70% for regional and 10% for the 
patients diagnosed at distant metastatic stage (7:11,17). 
In our study because of the limited number of conducted 
study in this filed and using different criteria for staging 
we can’t estimate the pooled survival rate of the colorectal 
cancer patient in a different stage.
A large number of studies were excluded due to the 
overlap of these studies by location and year of the study. 
Another limitation was that most of the studies were 
conducted in Tehran and we didn’t have sufficient data 
for other parts of the country. Also, some studies were 
reported the survival rate differently, for example, they 
reported only mean and median survival. 
In conclusion, the result of this study indicates that the 
1 and 3 year survival rate of the patients with colorectal 
cancer in Iran was similar to developed countries and 
5-year survival rate in our country was between developed 
and developing countries. The survival of colorectal 
cancer in all year in women was significantly better than 
man and the survival rate by tumor site was better in colon 
cancer than rectum cancer. 
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